SGMO - Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09 revenue of $28M beats by $0.64M

Sangamo Therapeutics press release (NASDAQ:SGMO): Q4 GAAP EPS of -$0.26 beats by $0.09. Revenue of $28M (+8.5% Y/Y) beats by $0.64M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $464.7 million, compared to $692.0 million as of December 31, 2020. "On a GAAP basis, we expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022."

For further details see:

Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M